

SUPPLEMENTARY MATERIAL**List of investigators****Belgium**

Daniel Blockmans	Leuven
Frédéric Vandergheynst	Brussels

Canada

Frederic Morin	Quebec
----------------	--------

Denmark

Jesper Noerregaard	Hillerod
--------------------	----------

France

Valerie Devauchelle Pensec	Brest
Eric Hachulla	Lille
Gilles Kaplanski	Marseille
Pierre Kieffer	Mulhouse
Claire Larroche	Bobigny
Alexis Regent	Paris

Germany

Rieke H.-E. Alten	Berlin
Martin Aringer	Dresden
Juergen Braun	Herne
Martin Fleck	Bad Abbach
Bernhard Hellmich	Plochingen
Joerg Christoph Henes	Tübingen
Jan Leipe	Munich
Frank Moosig	Bad Bramstedt
Thomas Neumann	Jena
Juergen Rech	Erlangen
Reinhold Ernst Schmidt	Hannover
Andreas Schwarting	Mainz
Reinhard Voll	Freiburg

Italy

Silvano Adami	Verona
Stefano Bombardieri	Pisa
Marco Amedeo Cimmino	Genova
Salvatore de Vita	Udine
Amelia Ruffatti	Padova
Maria Grazia Sabbadini	Milano
Carlo Salvarani	Reggio Emilia

Netherlands

Amanda J. W. Branten	Arnhem
Elisabeth Brouwer	Groningen

Edgar M. Colin
M. Vonk
Alexandre Voskuyl

Almelo
Nijmegen
Amsterdam

Norway

Maud-Kristine Ljoså
Geirmund Myklebust
Øyvind Palm

Ålesund
Kristiansand
Oslo

Poland

Marek Brzosko
Sławomir Jeka

Szczecin
Bydgoszcz

Portugal

António Marinho

Porto

Spain

Eduardo Ucar Angulo
Maria C. Cid
Francisco Javier Blanco Garcia
Francisco Javier Narvaez Garcia
Federico Diaz Gonzalez

Bilbao
Barcelona
A Coruna
Barcelona
La Laguna

Sweden

Peter Matt
Alladin Mohammad
Elisabeth Nordborg
Elke Theander
Ronald van Vollenhoven

Uppsala
Lund
Goteborg
Malmö
Stockholm

United Kingdom

Adewale Adebajo
Neil Basu
Paul Byrne
Bhaskar Dasgupta
David Hutchinson
Neil McKay
Susan Mollan
Ann Morgan
Pamela Peterson
Gordon Plant
Euthalia Roussou

Barnsley
Aberdeen
Colchester
Westcliffe-on-Sea
Truro
Edinburgh
Birmingham
Leeds
Newcastle upon Tyne
London
Romford

United States of America

Vera Bocoun
Lindsay Forbess
Joseph Z. Forstot
Daniel E Furst
William Gough
Jeffrey Kaine

Wausau
Los Angeles
Boca Raton
Los Angeles
Asheville
Sarasota

Brian Keroack
Curry Koenig
Eric Matteson
Peter Merkel
Christopher Phillips
Robert Spiera
John H. Stone
Andrew Sulich
Sebastian Unizony

Portland
Salt Lake City
Rochester
Philadelphia
Paducah
New York
Boston
St. Claire Shores
Boston

Box 1 Parameters tested as predictors of treatment failure**1. Patient-related features**

Age

Sex

Race

Body mass index

2. Disease-related features*At the time of GCA diagnosis*

Headaches

Scalp tenderness

Jaw claudication

GCA-related vision loss

Polymyalgia rheumatica symptoms

Temporal artery biopsy positive

Imaging demonstrating lesions compatible with large vessel vasculitis^a*At study baseline*

New-onset disease

Disease duration

Erythrocyte sedimentation rate

C-reactive protein level

3. Treatment-related features

Baseline prednisone dose

4. Patient-reported outcomes

Patient Global Assessment of Disease Activity

Functional Assessment of Chronic Illness Therapy–Fatigue score

36-Item Short Form Survey physical component summary

36-Item Short Form Survey mental component summary

EuroQol-5D score

^aImaging included computed tomography angiography, magnetic resonance angiography, and positron emission tomography

Table 1 GiACTA study definitions of patient-reported outcomes

Instrument	Description
Patient Global Assessment of Disease Activity (PtGA)	The PtGA score reflects patients' perceptions of their disease activity, ¹ which is marked on a numerical scale (0-100 mm). Higher numbers indicate perception that disease activity is worse.
Functional Assessment of Chronic Illness Therapy (FACIT)–Fatigue scale	The FACIT-Fatigue scale is a 13-item tool that measures a patient's level of fatigue during their usual daily activities in the past week. ² Fatigue and its impact on physical activity, functionality and social interactions are measured on a four-point Likert scale. The FACIT-Fatigue scale ranges from 0 to 52. Lower numbers indicate worse fatigue and greater impact of fatigue on physical, functional and social outcomes.
36-Item Short Form Survey (SF-36)	The SF-36 is a 36-item, patient-reported survey of functional health and well-being that captures data related to eight health domains (physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to emotional problems, emotional well-being, social functioning, energy/fatigue and perception of general health). ³ The SF-36 scores range from 0 to 100. Lower scores indicate less favourable health states.

EuroQol-5D (EQ-5D) score	The EQ-5D is a standardised instrument for measuring generic health status that gathers data regarding patient mobility, self-care, pain, depression/anxiety and usual activities (e.g. work, study, housework and family or leisure activities). ⁴ The EQ-5D score ranges from 0 to 1. Lower numbers indicate worse health status.
---------------------------------	--

Table 2 Causes of nonresponse to treatment

Cause, n (%)	PBO/PDN	TCZ/PDN
	N=101	N=149
Treatment failure	67 (66.3)	44 (29.5)
Refractory disease	31 (30.7)	18 (12.1)
Disease relapse	36 (35.6) [†]	26 (17.4) [‡]
Other	7 (6.9)	19 (12.8)
Treatment discontinuation because of an adverse event	3 (3.0)	8 (5.4)
Nonadherence to the protocol prednisone taper	1 (1)	4 (2.7)
Study withdrawal before week 52	2 (5.2)	4 (2.7)
Miscellaneous*	1 (1)	3 (2.0)

*Miscellaneous reasons included protocol violation and protocol noncompliance.

[†]Relapse in eight patients was based on isolated elevation of erythrocyte sedimentation rate.

[‡]Relapse in one patient was based on isolated elevation of erythrocyte sedimentation rate.

PBO/PDN, placebo + prednisone; TCZ/PDN, tocilizumab + prednisone.

REFERENCES

- 1 Nikiphorou E, Radner H, Chatzidionysiou K, *et al.* Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. *Arthritis Res Ther* 2016;18:251.
- 2 Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. *J Pain Symptom Manage* 1997;13:63-74.
- 3 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. *Med Care* 1992;30:473-83.
- 4 EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199-208.